Daiichi Sankyo Shares Jump

AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer
AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), in patients with a certain type of breast cancer. The drug, developed in partnership with Japan-based Daiichi Sankyo,
Daiichi Sankyo Shares Jump After U.S. FDA Approves Breast Cancer Drug
Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39, on Monday after rising as much as 9.7% earlier. Over the past three years, the stock posted a daily gain of more than 8% only four times.
AstraZeneca And Daiichi Sankyo's Datroway Gets US Approval For Metastatic HR+ Breast Cancer
British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab
FDA Approves AstraZeneca & Daiichi Sankyo’s Datroway for Metastatic Breast Cancer
The approval was based on results from the TROPION-Breast01 Phase III trial.
DATROWAY® Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
TOKYO, Japan & BASKING RIDGE, NJ, USA I January 17, 2055 I DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of
Datroway, 2nd ADC from AstraZeneca-Daiichi collab, wins first FDA nod in breast cancer
Following a world-first approval in Japan, AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate has crossed the U.S. regulatory finish line. | AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate,
AstraZeneca, Daiichi Sankyo win first U.S. approval for key cancer drug
A drug from AstraZeneca and Daiichi Sankyo won authorization for a form of breast cancer, the first U.S. approval for the closely watched treatment.
Hosted on MSN7d
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m
Daiichi Sankyo has finalised the acquisition of intellectual property rights for gatipotuzumab, an anti-tumour-associated ...
Pharmabiz7d
Daiichi Sankyo to pay $132.5 million to acquire IP rights for anti-TAMUC1 antibody in DS-3939 from Glycotope
Daiichi Sankyo to pay $132.5 million to acquire IP rights for anti-TAMUC1 antibody in DS-3939 from Glycotope: Tokyo Wednesday, January 15, 2025, 09:00 Hrs [IST] Daiichi Sankyo Com ...
Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH
Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual ...
ENDPOINTS NEWS7d
Dai­ichi Sankyo brings Gly­co­tope an­ti­body in-house for $132.5M
Daiichi Sankyo is spending $132.5 million to buy an antibody outright that it had already licensed from Glycotope.
Seeking Alpha25d
Daiichi Sankyo gets Japanese approval for Datroway
Daiichi Sankyo (OTCPK:DSKYF) stock slid 10% Friday after the Japanese drugmaker announced it had received approval in Japan for its DXd antibody-drug conjugate Datroway for the treatment of HR+ ...